Spain Viscosupplementation Market Size & Outlook
Spain viscosupplementation market, 2018-2030 (US$M)
Related Markets
Spain viscosupplementation market highlights
- The Spain viscosupplementation market generated a revenue of USD 53.9 million in 2023 and is expected to reach USD 109.7 million by 2030.
- The Spain market is expected to grow at a CAGR of 10.7% from 2024 to 2030.
- In terms of segment, three injection was the largest revenue generating product in 2023.
- Single Injection is the most lucrative product segment registering the fastest growth during the forecast period.
Viscosupplementation market data book summary
| Market revenue in 2023 | USD 53.9 million |
| Market revenue in 2030 | USD 109.7 million |
| Growth rate | 10.7% (CAGR from 2023 to 2030) |
| Largest segment | Three injection |
| Fastest growing segment | Single Injection |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Single Injection, Three Injection, Five Injection |
| Key market players worldwide | DePuy Synthes, Sanofi SA, Smith & Nephew PLC, Anika Therapeutics Inc, Zimmer Biomet Holdings Inc, Ferring, Lifecore Biomedical Inc, LG Chem, Roche Holding AG |
Other key industry trends
- In terms of revenue, Spain accounted for 1.1% of the global viscosupplementation market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, France viscosupplementation market is projected to lead the regional market in terms of revenue in 2030.
- France is the fastest growing regional market in Europe and is projected to reach USD 270.0 million by 2030.
Three injection was the largest segment with a revenue share of 42.67% in 2023. Horizon Databook has segmented the Spain viscosupplementation market based on single injection, three injection, five injection covering the revenue growth of each sub-segment from 2018 to 2030.
Primary care health records from over 3 million patients in northeast Spain showed that incidence rates per 1000 person per years for knee, hip, and hand osteoarthritis were 6.5. There are around six viscoelastic products composed of hyaluronic acid or its derivatives, which are commercially produced in Spain as health products (class III clinical implants) and which are being increasingly used in degenerative processes due to osteoarthrosis.
Mainly of the knee PRONOLIS HD, a newly released range of products of the Procare Health Iberia Company located in Spain, has been approved as the first high density HA gel with complete and innovative range of viscosupplementation.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Viscosupplementation Market Scope
Viscosupplementation Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Spain viscosupplementation market size, by product, 2018-2030 (US$M)
Spain Viscosupplementation Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
